The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD

The Screening and Analysis of Plasma Biomarkers in Irreversible Pulmonary Arterial Hypertension Associated With Congenital Heart Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02267200

Enrollment

Registered

2014-10-17

Start date

2014-10-31

Completion date

2016-09-30

Last updated

2016-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension,Pulmonary

Keywords

biomarkers，pulmonary arterial hypertension

Brief summary

The purpose of this study is to analyse the sensitivity and specificity of circulating endothelial cells to predict irreversible pulmonary arterial hypertension associated with congenital heart disease.

Detailed description

predict to recruit 100 patients with pulmonary arterial hypertension (PAH)associated with CHD，under the commitment of the children's parents，take 3-4ml central venous blood before the corrective surgery，then calculate the number of the circulating endothelial cells by flow cytometer AND detect the expression of micro RNAs to screen out the biomarker，through the 6 months follow-up, separated the reversible and irreversible PAH,then to carry on the statistics.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Months to 18 Years

Healthy volunteers

Inclusion criteria

* Only those patients with systolic PAP (sPAP) \>65mmHg before surgery were included.

Exclusion criteria

* Patients with trisomy 21 (Down syndrome) were not included

Design outcomes

Primary

Measure	Time frame	Description
the number of Circulation endothelial cells and the detective count of microRNAs	6 months after corrective surgery	the number of Circulation endothelial cells and the detective count of microRNAs in the biomarkers in both groups differd significantly.

Countries

China

Outcome results